neuro42 develops portable MRI systems and robotic intervention technology to enable bedside neuroimaging and interventions. Its compact Diagnostic MRI scanner is FDA 510(k) cleared for neuroimaging and is designed to enable rapid diagnosis at the patient’s bedside. The company has also built a robotic interventional module aimed at improving procedures such as brain biopsies and ablations. neuro42 is seeking regulatory clearance for its interventional module. Led by CEO and Founder Dr. Amit Vohra and based in San Francisco, the company intends to use new capital to accelerate development and bring solutions to patients. It recently received an investment from Zynext Ventures (amount undisclosed) to support that progress. neuro42 is a San Francisco-based medical technology company developing and commercializing an intraoperative MRI, artificial intelligence, and robotic platform for brain imaging and image-guided surgical interventions. The company is developing a first-of-its-kind MRI and robot that enables physicians to diagnose brain injury in acute settings and perform intraoperative treatments under live imaging. Its novel scanner allows robotic procedures outside the traditional magnetic resonance suite, expanding possibilities for intraoperative image guidance and disease treatment. neuro42's platform is portable, patient-centric, backed by over 30 patents, and targets conditions including stroke, hydrocephalus, epilepsy, and various brain tumors. The company intends to use financing to advance product development and scale deployment to physicians and neurosurgeons. To date the company has raised $7.8M, including an oversubscribed $1.3M seed round earlier this year and a recent $6.5M Series A.

Total raised

$7M

Funding rounds

2

Latest round

Series A

Latest activity

Jul 2021